Home/Filings/3/0001209191-18-052219
3//SEC Filing

Frazier Life Sciences VIII, L.P. 3

Accession 0001209191-18-052219

CIK 0001724344other

Filed

Sep 24, 8:00 PM ET

Accepted

Sep 25, 8:39 PM ET

Size

14.8 KB

Accession

0001209191-18-052219

Insider Transaction Report

Form 3
Period: 2018-09-25
Holdings
  • Series B-1 Tranche B Convertible Preferred Stock

    Common Stock (6,651,574 underlying)
  • Series B-1 Tranche A Convertible Preferred Stock

    Common Stock (5,212,833 underlying)
  • Series B Convertible Preferred Stock

    Common Stock (7,000,000 underlying)
Holdings
  • Series B-1 Tranche B Convertible Preferred Stock

    Common Stock (6,651,574 underlying)
  • Series B-1 Tranche A Convertible Preferred Stock

    Common Stock (5,212,833 underlying)
  • Series B Convertible Preferred Stock

    Common Stock (7,000,000 underlying)
Holdings
  • Series B Convertible Preferred Stock

    Common Stock (7,000,000 underlying)
  • Series B-1 Tranche B Convertible Preferred Stock

    Common Stock (6,651,574 underlying)
  • Series B-1 Tranche A Convertible Preferred Stock

    Common Stock (5,212,833 underlying)
Holdings
  • Series B-1 Tranche B Convertible Preferred Stock

    Common Stock (6,651,574 underlying)
  • Series B Convertible Preferred Stock

    Common Stock (7,000,000 underlying)
  • Series B-1 Tranche A Convertible Preferred Stock

    Common Stock (5,212,833 underlying)
Footnotes (2)
  • [F1]Each share of Series B Convertible Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock is convertible at any time, at the option of the holder, into Common Stock, on a 20.728-for-one basis, has no expiration date and will convert into shares of Common Stock upon the closing of the Issuer's initial public offering.
  • [F2]The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any.

Issuer

Entasis Therapeutics Holdings Inc.

CIK 0001724344

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001655827

Filing Metadata

Form type
3
Filed
Sep 24, 8:00 PM ET
Accepted
Sep 25, 8:39 PM ET
Size
14.8 KB